S. Flamm

1.0k total citations
18 papers, 184 citations indexed

About

S. Flamm is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, S. Flamm has authored 18 papers receiving a total of 184 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hepatology, 11 papers in Epidemiology and 2 papers in Infectious Diseases. Recurrent topics in S. Flamm's work include Hepatitis C virus research (15 papers), Liver Disease Diagnosis and Treatment (6 papers) and Liver Disease and Transplantation (4 papers). S. Flamm is often cited by papers focused on Hepatitis C virus research (15 papers), Liver Disease Diagnosis and Treatment (6 papers) and Liver Disease and Transplantation (4 papers). S. Flamm collaborates with scholars based in United States, France and Germany. S. Flamm's co-authors include F. Poordad, John G. McHutchison, E.J. Lawitz, Mark Sulkowski, Nezam H. Afdhal, Patrick Marcellin, Paul Y. Kwo, Michael P. Curry, Ira M. Jacobson and Stefan Zeuzem and has published in prestigious journals such as Journal of Hepatology, The American Journal of Gastroenterology and Transplantation.

In The Last Decade

S. Flamm

16 papers receiving 181 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Flamm United States	7	178	164	38	14	6	18	184
Gebeyehu Teferi United States	2	276 1.6×	253 1.5×	39 1.0×	8 0.6×	6 1.0×	2	283
H. Fontaine France	7	275 1.5×	265 1.6×	35 0.9×	17 1.2×	6 1.0×	22	286
Manal Abunimeh United States	6	336 1.9×	281 1.7×	99 2.6×	28 2.0×	6 1.0×	11	342
Carola Mix Germany	6	303 1.7×	288 1.8×	37 1.0×	20 1.4×	6 1.0×	13	320
Manuela Curescu Romania	9	259 1.5×	263 1.6×	29 0.8×	14 1.0×	3 0.5×	24	294
Elizabeth Akoth United States	5	241 1.4×	218 1.3×	41 1.1×	8 0.6×	6 1.0×	10	257
A. Osinusi Germany	5	137 0.8×	113 0.7×	24 0.6×	27 1.9×	8 1.3×	15	146
Miguel Ángel Von-Wichmann Spain	2	232 1.3×	204 1.2×	80 2.1×	13 0.9×	11 1.8×	2	250
Stephen Pianko Australia	2	102 0.6×	81 0.5×	42 1.1×	8 0.6×	4 0.7×	2	106
Lynn M. Frazier United States	6	277 1.6×	262 1.6×	61 1.6×	19 1.4×	8 1.3×	14	299

Countries citing papers authored by S. Flamm

Since Specialization

Citations

This map shows the geographic impact of S. Flamm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Flamm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Flamm more than expected).

Fields of papers citing papers by S. Flamm

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Flamm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Flamm. The network helps show where S. Flamm may publish in the future.

Co-authorship network of co-authors of S. Flamm

This figure shows the co-authorship network connecting the top 25 collaborators of S. Flamm. A scholar is included among the top collaborators of S. Flamm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Flamm. S. Flamm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Brown, Robert S., et al.. (2025). Screening and management of portal hypertension and varices in cirrhosis: Expert perspectives. Hepatology Communications. 9(4).

Younossi, Zobair M., Maria Stepanova, Ira M. Jacobson, et al.. (2017). High efficacy is accompanied with substantial gains in patient reported outcomes in cirrhotic patients with chronic hepatitis C treated with sofosbuvir (SOF), velpatasvir with or without voxilaprevir (VOX): data from POLARIS 1, 2, 3 and 4. Journal of Hepatology. 66(1). S114–S114. 1 indexed citations

Younossi, Zobair M., B. Bacon, Michael P. Curry, et al.. (2017). Elbasvir/Grazoprevir effectiveness in patients with Chronic Hepatitis C and Chronic Kidney Disease: real-world experience from the TRIO Network. Journal of Hepatology. 66(1). S748–S749. 2 indexed citations

Sarrazin, C., Michael P. Manns, Kris V. Kowdley, et al.. (2017). No impact of RASs on the high efficacy of SOF/VEL/VOX for 12 weeks in DAA-experienced patients: an integrated resistance analysis of the POLARIS-1 and POLARIS-4 studies. Journal of Hepatology. 66(1). S299–S299. 6 indexed citations

Lawitz, Eric, Marc Bourlière, Lingling Han, et al.. (2017). Treatment with SOF/VEL or SOF/VEL/VOX is well tolerated and results in high SVR12 in genotype 1–6 HCV infected patients with minimal fibrosis: a retrospective analysis of the ASTRAL and POLARIS clinical studies. Journal of Hepatology. 66(1). S310–S311.

Tapper, Elliot B., Marı́a Buti, Jean‐François Dufour, et al.. (2016). The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis. Transplantation. 101(5). 987–995. 16 indexed citations

Sulkowski, Mark, S. Flamm, Zeid Kayali, et al.. (2016). Short‐duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study). Liver International. 37(6). 836–842. 23 indexed citations

Tapper, Elliot B., et al.. (2016). The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients with Child B and C Cirrhosis: A Cost-Effectiveness Analysis. Journal of Hepatology. 64(2). S800–S800. 3 indexed citations

Samuel, Didier, Michael Manns, Xavier Forns, et al.. (2015). P0774 : Ledipasvir/sofosbuvir with ribavirin is safe in >600 decompensated and post liver transplantation patients with HCV infection: An integrated safety analysis of the solar 1 and solar 2 trials. Journal of Hepatology. 62. S620–S621. 15 indexed citations

10.

Kowdley, Kris V., B. Bacon, Doug Dieterich, et al.. (2015). P0867 : Efficacy evaluation of 24 week SOF + RBV in a heterogeneous, real-world population of genotype 3 HCV patients; Data from the trio network. Journal of Hepatology. 62. S665–S666. 1 indexed citations

11.

Forns, Xavier, David Mutimer, Michael P. Manns, et al.. (2015). P0779 : Ledipasvir/sofosbuvir with ribavirin for the treatment of fibrosing cholestatic hepatitis C after liver transplantation. Journal of Hepatology. 62. S623–S623. 6 indexed citations

12.

Zeuzem, Stefan, F. Poordad, J.‐P. Bronowicki, et al.. (2013). 1430 SAFETY AND EFFICACY OF BOCEPREVIR/PEGINTERFERON/ RIBAVIRIN (BOC/P/R) COMBINATION THERAPY FOR CHRONIC HCV G1 PATIENTS WITH COMPENSATED CIRRHOSIS: A META-ANALYSIS OF FIVE PHASE 3 CLINICAL TRIALS. Journal of Hepatology. 58. S576–S577. 8 indexed citations

13.

Pol, S., Maciej Jabłkowski, Bittoo Kanwar, et al.. (2013). 68 ANTIVIRAL EFFICACY OF THE NS3 PROTEASE INHIBITOR, GS-9451, NON-NUCLEOSIDE NS5b INHIBITOR, TEGOBUVIR, AND PEGYLATED INTERFERON PLUS RIBAVIRIN IN TREATMENT-NAÏVE GENOTYPE 1 HEPATITIS C INFECTED PATIENTS. Journal of Hepatology. 58. S31–S31. 4 indexed citations

14.

Bronowicki, J.-P., Mitchell Davis, S. Flamm, et al.. (2012). 11 SUSTAINED VIROLOGIC RESPONSE (SVR) IN PRIOR PEGINTERFERON/RIBAVIRIN (PR) TREATMENT FAILURES AFTER RETREATMENT WITH BOCEPREVIR (BOC)-+-PR: THE PROVIDE STUDY INTERIM RESULTS. Journal of Hepatology. 56. S6–S6. 31 indexed citations

15.

Flamm, S., E. Läwitz, Ira M. Jacobson, et al.. (2011). 1366 HIGH SUSTAINED VIROLOGIC RESPONSE (SVR) AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2A/RIBAVIRIN. Journal of Hepatology. 54. S541–S542. 19 indexed citations

16.

Schiff, E., F. Poordad, Ira M. Jacobson, et al.. (2008). 104 BOCEPREVIR (B) COMBINATION THERAPY IN NULL RESPONDERS (NR): RESPONSE DEPENDENT ON INTERFERON RESPONSIVENESS. Journal of Hepatology. 48. S46–S46. 37 indexed citations

17.

Gleason, Briana C., et al.. (2004). Secondary IgA nephropathy presenting as nephrotic syndrome with glomerular crescentic changes and acute renal failure in a patient with autoimmune hepatitis. Journal of Nephrology. 17(1). 125–129. 6 indexed citations

18.

Flamm, S.. (1998). Risk Factors Associated With Chronic Hepatitis C Virus Infection: Limited Frequency of an Unidentified Source of Transmission. The American Journal of Gastroenterology. 93(4). 597–600. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact